Quick Answer
Monopar Therapeutics reported Total Assets of $140.72 million for fiscal year 2025.
Monopar Therapeutics Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $140.72M | +133.4% |
| 2024 | $60.29M | +720.8% |
| 2023 | $7.35M | -44.5% |
| 2022 | $13.23M | -35.5% |
| 2021 | $20.52M | +21.7% |
| 2020 | $16.87M | +26.3% |
| 2019 | $13.35M | +82.5% |
| 2018 | $7.32M | -26.3% |
| 2017 | $9.93M | +243.0% |
| 2016 | $2.90M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $144.20M | +2275.7% | +167.7% |
| June 30, 2025 | $53.87M | +650.2% | -2.2% |
| March 31, 2025 | $55.09M | +518.1% | -8.6% |
| December 31, 2024 | $60.29M | +720.8% | +893.3% |
| September 30, 2024 | $6.07M | -29.4% | -15.5% |
| June 30, 2024 | $7.18M | -30.6% | -19.4% |
| March 31, 2024 | $8.91M | -24.7% | +21.3% |
| December 31, 2023 | $7.35M | -44.5% | -14.5% |
- Monopar Therapeutics showed an increase of +133.4% in Total Assets compared to the prior fiscal year.
- Over the 2016–2025 period, Monopar Therapeutics’s total assets has grown by 4759.8% (from $2.90 million to $140.72 million).
- The most recent figure is from Monopar Therapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: